Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...
Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...
On June 9, 2025, clinicians, research trainees, and physician-scientists came together to present research and findings in the field of spine surgery at SpineFEST 2025. Hosted by the U of T Spine ...
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment ...
The various roles for oncology nurses in the conduct of clinical trials were described in a presentation at the 2025 ONS Bridge virtual meeting.
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...
People with MS experience significant changes in cognition more than a year before significant physical decline is evident, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback